MiNK Therapeutics Accelerates Innovation with Impressive Q1 2026 Milestones
At its recent Q1 2026 conference call, MiNK Therapeutics unveiled an impressive array of achievements that solidify its position as a leader in the field of off-the-shelf invariant natural killer T (iNKT) cell therapies.
During the call, Dr. Jennifer Buell, President and Chief Executive Officer, highlighted the company's significant progress over the past few weeks. MiNK presented data at four major international scientific meetings, including findings in pulmonary fibrosis at the Keystone Symposia in February, phase II clinical data in refractory gastric cancer at AACR in April, and mechanistic findings at the American Society for Gene & Cell Therapy just earlier this week.
The company's presentation of a combination of its iNKT technology, AGENT-797, with an IL-15 superagonist named ANKTIVA showed promising results in modulating dysregulated inflammation and pathogen-clearing responses in severe pulmonary fungal infection. This data further reinforces the potential of MiNK's therapies to address diseases characterized by immune failure, inflammatory injury, and impaired pathogen control.
One of the key differentiators of MiNK's platform is its practicality, which has allowed the company to evaluate its living medicines and diseases in clinical environments that were previously impractical for cell therapy due to operational complexity and cost. This practicality is central to how MiNK is expanding its platform through selective partnerships.
In the first quarter of this year, MiNK announced a collaboration with C-Further to advance their PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. This program brings non-dilutive support and potential meaningful commercial economics while applying MiNK's off-the-shelf iNKT platform to a setting where speed, tolerability, and access matter profoundly.
Dr. Terese Hammond, Head of Development, will present at the American Thoracic Society Conference next week, describing a combination of MiNK's iNKT technology with an IL-15 superagonist in severe pulmonary fungal infection. This presentation further emphasizes the potential of MiNK's therapies to address diseases characterized by immune failure and impaired pathogen control.
At AACR in April, investigators from Memorial Sloan Kettering presented data from MiNK's phase II study in gastroesophageal cancer. The population was heavily pretreated, checkpoint refractory, with historically poor expected outcomes and limited therapeutic options after failure on prior first-line therapy. MiNK observed prolonged survival in patients who received induction immune therapy prior to chemotherapy, including emergence of a meaningful tail of the survival curve.
These recent milestones demonstrate MiNK's commitment to advancing innovation in the field of off-the-shelf iNKT cell therapies and its potential to address some of the world's most pressing diseases. As the company continues to push boundaries and expand its platform through strategic partnerships, it is clear that MiNK Therapeutics remains at the forefront of this exciting and rapidly evolving field.
